User:N0945

Winship Cancer Institute
The Winship Cancer Institute in Atlanta, Georgia is a Cancer Center designated by the National Cancer Institute. It is situated on the Emory University campus, and along with Emory University Hospital, Emory University Hospital Midtown, and The Emory Clinic it is a part of Emory Healthcare and its parent organization, the Woodruff Health Sciences Center. The physicians at Winship hold faculty appointments at the Emory University School of Medicine. Winship uses a translational and interdisciplinary approach to treating many different types of cancer.

The Winship Cancer Institute also works closely on research and care initiatives with the Georgia Cancer Coalition and the American Cancer Society.

The Robert Winship Memorial Clinic (now the Winship Cancer Institute) was founded at Emory University in 1937 with a gift from Robert Woodruff, former president of Coca-Cola. The Clinic was named in honor of Mr. Woodruff's maternal grandfather, Robert Winship.

The Winship Cancer Institute employs about X amt of people and has annual revenues of about $XM. There are more than X number of patient visits per year, and it is involved in x amount of clinical trials. The Winship Cancer Institute is internationally renowned for its cancer treatment and research.

In addition to being an NCI-designated National Cancer Institute, In its first year of operation in 1939, the clinic had 4 people on staff, and treated 168 patients.

History of Winship
1937: The Robert Winship Memorial Clinic is founded at Emory University with a gift from Robert Woodruff. Woodruff, the president of Coca-Cola, had lost his mother to cancer that year. The Clinic is named in honor of Mr. Woodruff's maternal grandfather, Robert Winship.

1938: Dr. Elliott Scarborough begins his tenure as the clinic's first doctor and director. The clinic opens in a sun porch at the end of the east wing of Emory Hospital, adjacent to the emergency department. It has four people on staff.

1939: In its first year, the clinic treats 168 patients.

1949: Dr. Scarborough is named to the National Advisory Cancer Council, a group of experts who advise federal agencies on policy issues, now known as the National Advisory Cancer Board.

1951: Experts refer to Winship Cancer Clinic as "one of the best in the nation."

1954: Dr. Scarborough publicly declares he is convinced that smoking cigarettes causes lung cancer. This statement comes at one of his many public appearances, intended to educate the public about cancer prevention and treatment.

1955: Dr. Scarborough is appointed to the board of directors of the American Cancer Society.

1964: The number of patients treated has risen to nearly 15,000 per year.

1966: The Winship Cancer Clinic relocates into the Emory Clinic.

1966: Dr. Scarborough dies of pancreatic cancer. He is posthumously awarded the 1967 Shining Light Award for his service to the Atlanta community.

1985: The Clinic is renamed the Winship Cancer Center and becomes more integrated into Emory University Hospital. It also begins coordinating cancer research and treatment for Emory, Crawford Long (now Emory Hospital Midtown) and Grady hospitals and the Atlanta Veterans Affairs Medical Center.

1999: Dr. Jonathon W. Simons, a highly acclaimed physician-scientist who specializes in translational research, is named the Center's new director. The Center changes its name to Winship Cancer Institute.

2003: Winship opens a new, 280,000-square-foot, state-of-the-art facility. Its new home houses all original departments plus additional research and high-tech treatment facilities.

2004: Winship, in collaboration with Georgia Tech, receives a $10 million NIH grant to study how nanotechnology -- the use of microscopic machines -- can help fight prostate cancer.

2005: Chemical Biology Discovery Center selected by SAIC-Frederick, Inc. (SAIC-F) to be part of an 11-member national consortium aimed at accelerating the discovery and development of new and innovative, targeted cancer therapies. The national Chemical Biology Consortium (CBC) will bridge the gap between basic scientific investigation and clinical research supported by the NCI and focus on unmet needs needs such as drugs that are of low interest to pharmaceutical industry, but could have significant benefit for patients.

2006: NCI selects the Emory and Georgia Tech joint research program as one of seven National Centers of Cancer Nanotechnology Excellence (CCNE)

2007: The National Cancer Institute awards a five-year, $12.5 million Specialized Program of Research Excellence (SPORE) grant in head and neck cancer to Winship Cancer Institute. This is the first SPORE grant ever received in the state of Georgia.

2008: Blue Cross and Blue Shield of Georgia recognizes Winship Cancer Institute as a Blue Distinction Center for Complex and Rare Cancers, focusing on complex inpatient and surgical care. Winship is the only facility in the metropolitan Atlanta area and one of only 85 in the United States to earn this designation.

2009 Winship announces cancer center designation by the National Cancer Institute (NCI), and opens Phase I Clinical Trials Unit. Walter J. Curran, MD, Chairman of department of radiation oncology at Emory, appointed new Director of Winship. Department of Radiation Oncology earned provisional full membership in the Radiation Therapy Oncology Group (RTOG) joining 28 American and 7 Canadian institutions in this honor. Surgeon Keith Delman and Urologist Viraj Master devise less invasive procedure for complete lymph node removal in the groin (inquino-femoral lymphadenectome). Imaging Technology News names Emory's Department of Radiation Oncology to its "Top Five Radiation Therapy Centers to Watch in 2009". Winship becomes the first location in Georgia to use new and faster radiation system, called RapidArc, which can reduce treatment times and deliver a complete treatment in a single rotation of the machine around the patient. This treatment is used for prostate cancer, head and neck cancers, and brain tumors.

Research at Winship: Highlights

 * Helped develop lifesaving procedures including angioplasty and drug-eluting stents, and newer technologies such as off-pump surgery.
 * Created lamivudine (3TC) and emtricitabine (FTC), two of the most commonly used and most successful HIV/AIDS drugs, taken by more than 94% of U.S. patients on therapy and by thousands more around the world
 * Developed one of the leading vaccine candidates against HIV, already tested in preclinical and early stage clinical trials and currently in phase II trials
 * Developed brain mapping to guide effective surgical approaches (deep brain stimulation) to treat movement disorders such as Parkinson's and dystonia
 * Discovered the gene responsible for fragile X syndrome, the most common cause of inherited intellectual disability, and now working to develop drug therapy to treat it.
 * Helped develop belatacept, a post-transplant drug that is less toxic and more effective than current immunosuppressants.
 * Discovered the role of PD-1 (programmed cell death 1) in inhibiting the T cell immune response to chronic viral infections.
 * Discovered in the laboratory, then in early-stage clinical trials, the beneficial effects of progesterone to treat traumatic brain injury, the first new treatment for TBI in 30 years. Currently leading a large nationwide NIH-supported clinical trial of progesterone and TBI.
 * Developing an effective method of using deep-brain stimulation as therapy for treatment-resistant severe depression.

Research Leadership

 * The Yerkes National Primate Research Center of Emory University is one of eight NIH-designated national primate research centers in the country.
 * Emory is one of eight NIH-sponsored Vaccine Evaluation and Treatment Units (VTEUs) conducting clinical trials for vaccines for infectious diseases, including H1N1 flu.
 * Emory is a leader in technology transfer, with 27 products in the marketplace and 11 more in human clinical trials. Since 1992, Emory has launched 47 start-up companies and has received $775.4 million from the commercialization of its technologies.
 * The research partnership between Emory and Georgia Tech includes the No. 2-ranked (U.S. News & World Report) Wallace H. Coulter Department of Biomedical Engineering, the Georgia Tech-Emory Center for Regenerative Medicine (GTEC), the Emory/Georgia Tech Predictive Health Institute, and one of the nation's largest NIH-funded research programs in nanomedicine.

External Research Funding
(Emory University total external research funding, FY09: $484.2 million) (Emory University total federal funding, FY09: $343.6 million) (Emory University total research proposals submitted, FY09: $1 billion) NIH Funding
 * Woodruff Health Sciences Center external research funding, FY09: $446.5 million
 * Woodruff Health Sciences Center funding by federal agencies, FY09: $320.1 million
 * Woodruff Health Sciences Center research proposals submitted, FY09: $911.6 million
 * Emory University total American Recovery and Reinvestment Act (ARRA) to date: $77 million
 * Emory University ranks 18th among all organizations in NIH grant funding: $306,614,245
 * Emory School of Medicine ranks 15th in NIH grant funding to medical schools: $265,256,173

Adult Cancer Care at Winship
Adult cancer treatment is the focus of Winship's efforts. The Winship Cancer Institute has highly skilled and specialized surgical oncologists, hematological oncologists, bone marrow transplant doctors, radiation oncologists, and medical oncologists. The Emory Breast Center offers imaging, multidisciplinary care, treatment options, and advice to women with breast cancer. The

Pediatric Cancer Care at Winship
Winship partners with Children's Healthcare of Atlanta, located just across the street from the Emory University undergraduate campus. In addition, Winship partners with CHOA to offer a Young Adult Cancer Survivor Clinic to follow those pediatric patients who have celebrated a milestone of years disease-free but need the support and medical supervision of a specialized team trained to recognize late-effect symptoms of pediatric cancer treatment. Winship is also working with CHOA to develop a transition program to transition these pediatric cancer survivors to the care of Winship as they progress in age beyond pediatric medicine.

Survivorship Program
In addition to being innovative and providing high quality procedures, Winship also focuses on patient survivorship and understanding patients' needs after cancer treatment is complete. Winship provides many resources for cancer survivors, including workshops and NCI survivorship resources. Patients can find information on the following topics:

•   Relationships •   Physical condition •   Emotional concerns •   Diet, nutrition and exercise •   Finances and careers •   Follow-up care 4